China’s Digital Healthcare Opportunities and Regulatory Implications

Outlook Google (online)


Full Dates


Business Meetings


Medical Device & Digital Health

Event Code




Contact us for more details and prices

More Information

China’s Digital Healthcare Opportunities and Regulatory Implications

Expand All

China’s Digital Healthcare Opportunities and Regulatory Implications



o The rise of China’s digital economy in healthcare:

- The broader China health opportunity set

Telehealth, telemedicine, internet hospitals and distance health services – what are they and what are we seeing in China?

- Digital therapeutics and diagnostics, and AI-assisted and deep learning growth areas – what are they and what are we seeing in China

o What are the regulatory implications?

- Starting point is still the traditional classification rules for Life Sciences products in China

- Regulatory developments adapting to the digital economy:

software as medical device (SaMD)

software in a medical device (SiMD)

Deep-learning and AI products

Universal Device Identifiers (UDI)

Some digital developments at the regulator: online applications and certificates

o But, conversely the strengthening of some on-site, in-person requirements such as overseas factory inspections

o Increasing focus on PMS requirements, adapting to full product lifecycle regulation

- Legal agent role importance

o Increased emphasis on regulatory fast-track for innovative products, although not all the hype is justified:

- Hainan Boao Lecheng International Medical Tourism Zone

- Green pathway for innovative medical devices

- Registration through Hong Kong and Greater Bay Area / Pearl River Delta

o where are the regulatory gaps?

- Keeping software and AI-registrations current: due to the continual update process of digital products, the legacy regulatory frame

Brief About Cisema:

Cisema is a turn-key regulatory affairs solutions provider for China and Hong Kong for medical devices, IVDs, pharmaceutical packaging & APIs and other life science products. Founded in 2002 in Munich, Germany and Beijing, China, we have offices globally. We’re a one-stop service provider supporting Israeli and global companies register their products for sale in China (including clinical studies). Cisema also provides post-market surveillance support and can act as legal agent.


Nov 3, 2020 10:00 AM in Jerusal

For Regisration Click Here

Contact us

I confirm receipt of direct mail from the Export Institute
FullNameNotTyped PhoneNotTyped SubjectNotSelected

Thank You!